The FDA approval was based on data from a randomized, multi-arm, controlled clinical trial (n=1,879) that showed using Tegaderm CHG IV Securement Dressing lowered CRBSI by 60% in patients with ...

The expanded indication is supported by a randomized, multi-arm, controlled clinical trial of 1,879 subjects that found Tegaderm CHG I.V. Securement Dressing reduced CRBSI by 60 percent in ...

To address the growing concern of PIV complications, 3M has introduced 3M™ Tegaderm™ Antimicrobial I.V. Advanced Securement Dressing and 3M™ Tegaderm™ Antimicrobial Transparent Dressing to ...

It concluded that Tegaderm CHG could generate cost savings of £73 per patient when the baseline CRBSI rate was 1.48 per 1,000 catheter days, as cited in the Matching Michigan study for intensive care ...

Tegaderm ® application was associated with significantly lower daily weight loss throughout the first week of life (P=0.04; data not shown). TEG infants also regained their birth weight faster ...

NICE has assessed the 3M Tegaderm CHG IV securement dressing (Tegaderm CHG) for central venous and arterial catheter insertion sites to help the NHS decide whether to use this product. Tegaderm CHG is ...